Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2020 Nov;123(10):1496-1501.
doi: 10.1038/s41416-020-01033-x. Epub 2020 Sep 1.

Pre-clinical animal models are poor predictors of human toxicities in phase 1 oncology clinical trials

Affiliations
Meta-Analysis

Pre-clinical animal models are poor predictors of human toxicities in phase 1 oncology clinical trials

Johnique T Atkins et al. Br J Cancer. 2020 Nov.

Abstract

Background: Our objective was to determine the correlation between preclinical toxicity found in animal models (mouse, rat, dog and monkey) and clinical toxicity reported in patients participating in Phase 1 oncology clinical trials.

Methods: We obtained from two major early-Phase clinical trial centres, preclinical toxicities from investigational brochures and clinical toxicities from published Phase 1 trials for 108 drugs, including small molecules, biologics and conjugates. Toxicities were categorised according to Common Terminology Criteria for Adverse Events version 4.0. Human toxicities were also categorised based on their reported clinical grade (severity). Positive predictive values (PPV) and negative predictive values (NPV) were calculated to determine the probability that clinical studies would/would not show a particular toxicity category given that it was seen in preclinical toxicology analysis. Statistical analyses also included kappa statistics, and Matthews (MCC) and Spearman correlation coefficients.

Results: Overall, animal toxicity did not show strong correlation with human toxicity, with a median PPV of 0.65 and NPV of 0.50. Similar results were obtained based on kappa statistics and MCC.

Conclusions: There is an urgent need to assess more novel approaches to the type and conduct of preclinical toxicity studies in an effort to provide better predictive value for human investigation.

PubMed Disclaimer

Conflict of interest statement

Dr. LoRusso reports the following financial disclosures: Advisory Board Member - AbbVie (2018-2019), GenMab (2016-2019), Genentech (2016-2019), CytomX (2016-2019), Takeda (2017-2020), Cybrexa (2018-2019), Agenus (2018-2020), IQVIA (2019-2020), TRIGR (2019-2020), Pfizer (2019-2020), I-MAB (2019-2020), ImmunoMet (2018-2020), Black Diamond (2019-2020), Glaxo-Smith Kline (2019-2020), QED Therapeutics (2019-2020), AstraZeneca (2019-2020), EMD Serono (2019-2020), Shattuck (2019-2020), Astellas (2019-2020), Salarius (2019-2020), Silverback (2019-2020), MacroGenics (2019-2020), Kyowa Kirin Pharmaceutical Development (2020-2021), Kineta, Inc. (2020-2021), Zentalis Pharmaceuticals (2020-2021), Molecular Templates (2020-2021); Data Safety Monitoring Board – Agios (2016-2019), Halozyme (2016-2019); Data Safety Monitoring Committee - Five Prime (2017-2020), Tyme (2018-2020); imCORE Alliance - Roche-Genentech (2016-2019); SOTIO Consultant (2018-2019). Dr. Hong reports grants from Bayer, Lilly, Genentech, LOXO, Pfizer, Amgen, Mirati, Ignyta, Merck, Daichii-Sanko, Eisai, Adaptimmune, Abbvie, Astra-Zeneca, BMS, Genmab, Infinity, Kite, Kyowa, Medimmune, Molecular Template, Novartis, Takeda, personal fees from Mirna, LOXO, other from Bayer, Baxter, Guidepoint global, Oncoresponse, Janssen, Molecular Match, outside the submitted work. The other authors have declared no conflicts.

Figures

Fig. 1
Fig. 1. Bar charts show proportion of drugs with reported toxicity in humans and in each animal model.
Blue bars: humans; red: mouse; green: rat; purple: dog, light blue: monkey.
Fig. 2
Fig. 2. Box and whisker plots show quartiles of the distribution of positive predictive values (PPVs) and negative predictive values (NPV) of human toxicities based on animal toxicities.
For each animal model, a PPV for all toxicity grades (median: dog = 0.67, monkey = 0.72, mouse = 0.57, rat = 0.65), b PPV for grade 3 and 4 toxicities (median: dog = 0.38, monkey = 0.60, mouse = 0.43, rat = 0.41), c NPV for all toxicity grades (median: dog = 0.52, monkey = 0.50, mouse = 0.57, rat = 0.51), and d NPV for grade 3 and 4 toxicities (median: dog = 0.71, monkey = 0.73, mouse = 0.81, rat = 0.72).
Fig. 3
Fig. 3. PPV and NPV show the likelihood of each category of toxicity as seen in humans.
a PPV for all toxicity grades, b PPV for grade 3 and 4 toxicities, c NPV for all toxicity grades, and d NPV for grade 3 and 4 toxicities. The circles in this figure represent the different animal model systems. Abbreviations: hem, haematologic; cvd, cardiovascular; gi, gastrointestinal; hep, hepatic; neu, neurologic/psychiatric; cut, cutaneous; ren, renal; met, metabolic; gen, general; ms, musculoskeletal; rsp, respiratory; end, endocrine; eye, ocular.

References

    1. Roskoski R. Properties of FDA-approved small molecule protein kinase inhibitors. Pharm. Res. 2019;144:19–50. doi: 10.1016/j.phrs.2019.03.006. - DOI - PubMed
    1. FDA. Biological Product Definitions: FDA; https://www.fda.gov/files/drugs/published/Biological-Product-Definitions.... (2020).
    1. Chau CH, Steeg PS, Figg WD. Antibody-drug conjugates for cancer. Lancet. 2019;394:793–804. doi: 10.1016/S0140-6736(19)31774-X. - DOI - PubMed
    1. Dueck AC, Mendoza TR, Mitchell SA, Reeve BB, Castro KM, Rogak LJ, et al. Validity and reliability of the US National Cancer Institute’s Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) JAMA Oncol. 2015;1:1051–1059. doi: 10.1001/jamaoncol.2015.2639. - DOI - PMC - PubMed
    1. Hillman SL, Mandrekar SJ, Bot B, DeMatteo RP, Perez EA, Ballman KV, et al. Evaluation of the value of attribution in the interpretation of adverse event data: a North Central Cancer Treatment Group and American College of Surgeons Oncology Group investigation. J. Clin. Oncol. 2010;28:3002–3007. doi: 10.1200/JCO.2009.27.4282. - DOI - PMC - PubMed

Publication types

MeSH terms

Substances